Qinli Biotechnology Co., Ltd. aims to create a distinctive and competitive biotechnology company. In the clinical testing market, central fully automated instruments with a large number of rapid testing functions dominate most of the market, just as supercomputers in early information systems were dominated by large companies. Biosensors are just like current personal computers, and can be widely accepted by the public around the world and have a huge growth rate.

The company's research and development is aimed at two major fields. One is based on screen printing electrode technology and key electrochemical detection technologies, combined with the advantages of domestic electronic technology, and develops biosensor products for clinical, environmental protection, national defense, animal use, agricultural use, and gene use. Testing and other fields. Based on the technical platform developed by the company, any company that has electrochemical activity in the detection project itself or can produce electrochemical activity through enzymes or other special reactions is capable of developing relevant biosensors. The second is microbial and genetic engineering technology, the development of healthy food and clinical immunoassay reagents. Company culture lies in cultivating the vitality of continuous innovation and pursuit of excellence, and contributing to the enhancement of human health and quality of life.